E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $9.09
    +0.21 (+2.36%)

    Market Cap: $600.40M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(18/35)
    Avg Surprise
    -12.37%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.06
    Range$-0.08 - $-0.04
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.07-16.7%
    60d ago$-0.07-16.7%
    30d ago$-0.07-16.7%
    7d ago$-0.06+0.0%
    Current$-0.06
    Revenue Consensus
    $78M
    Range$77M - $80M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.18
    Range$0.12 - $0.20
    5 analysts
    Revenue Consensus
    $103M
    Range$102M - $104M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.18---
    Sep 26EST
    		-$-0.06---
    Jun 26
    Reported Aug 5
    		$-0.09$-0.09+0.00%Beat+65.4%
    Mar 26
    Reported May 4
    		$-0.05N/A+58.33%Beat+70.6%
    Dec 25
    Reported Mar 3
    		$0.01N/A-64.61%Miss-5.0%
    Sep 25
    Reported Nov 5
    		$-0.20$-0.26+23.08%Beat-11.1%
    Jun 25
    Reported Aug 5
    		$-0.26$-0.09-188.89%Miss-333.3%
    Mar 25
    Reported May 7
    		$-0.17$-0.14-21.43%Miss-54.5%
    Dec 24
    Reported Mar 4
    		$0.01$0.02-37.67%Miss+111.6%
    Sep 24
    Reported Nov 6
    		$-0.18$-0.11-63.64%Miss+0.0%
    Jun 24
    Reported Jul 31
    		$-0.06$-0.06+0.00%Beat+72.7%
    Mar 24
    Reported May 7
    		$-0.11$-0.08-37.50%Miss+35.3%
    Dec 23
    Reported Mar 7
    		$-0.12$-0.07-71.43%Miss+14.3%
    Sep 23
    Reported Nov 7
    		$-0.18$-0.18+0.00%Beat+37.9%
    Jun 23
    Reported Aug 2
    		$-0.22$-0.20-10.00%Miss+26.7%
    Mar 23
    Reported May 9
    		$-0.17$-0.16-6.25%Miss+29.2%
    Dec 22
    Reported Mar 8
    		$-0.14$-0.15+6.67%Beat+41.7%
    Sep 22
    Reported Nov 8
    		$-0.29$-0.29+0.00%Beat-3.6%
    Jun 22
    Reported Aug 2
    		$-0.30$-0.24-25.00%Miss-57.9%
    Mar 22
    Reported May 10
    		$-0.24$-0.33+27.27%Beat-20.0%
    Dec 21
    Reported Mar 3
    		$-0.24$-0.21-14.29%Miss+45.5%
    Sep 21
    Reported Nov 2
    		$-0.28$-0.27-3.70%Miss+15.2%
    Jun 21
    Reported Aug 4
    		$-0.19$-0.25+24.00%Beat+55.8%
    Mar 21
    Reported May 12
    		$-0.20N/A+53.49%Beat+73.3%
    Dec 20
    Reported Mar 24
    		$-0.44$-0.22-100.00%Miss+13.7%
    Sep 20
    Reported Oct 29
    		$-0.33$-0.37+10.81%Beat+65.6%
    Jun 20
    Reported Aug 10
    		$-0.43$-0.69+37.68%Beat+67.4%
    Mar 20
    Reported May 11
    		$-0.75$-0.62-20.97%Miss+8.5%
    Dec 19
    Reported Feb 25
    		$-0.51$-0.68+25.00%Beat-10.9%
    Sep 19
    Reported Nov 4
    		$-0.96$-1.14+15.79%Beat-152.6%
    Jun 19
    Reported Aug 12
    		$-1.32$-0.84-57.14%Miss-277.1%
    Mar 19
    Reported Apr 30
    		$-0.82$-0.62-32.26%Miss-173.3%
    Dec 18
    Reported Mar 18
    		$-0.46$-0.55+16.36%Beat-64.3%
    Sep 18
    Reported Nov 5
    		$-0.38$-0.42+9.52%Beat-46.2%
    Jun 18
    Reported Aug 2
    		$-0.35$-0.32-9.38%Miss-29.6%
    Mar 18
    Reported May 10
    		$-0.30$-0.36+16.67%Beat-76.5%
    Dec 17
    Reported Feb 9
    		$-0.28$-0.30+6.67%Beat-
    Sep 17
    Reported Nov 29
    		$-0.26$0.00N/AMiss-
    Jun 17
    Reported Aug 28
    		$-0.27$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-27.82EV/EBITDA-21.50x
    Price/FCF-27.37xFCF Yield-3.65%
    Profitability
    Profit Margin-10.80%Operating Margin-5.17%
    ROE-18730.00%ROIC-14.93%
    Financial Health
    Debt/Equity-5.07xInterest Coverage-1.16x
    Current Ratio1.70xQuick Ratio1.28x
    Trading Statistics
    Beta1.36Avg Volume1.19M
    52-Week High$9.1552-Week Low$3.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.69
    SMA 20$8.11
    SMA 50$7.09
    SMA 200$6.02
    EMA 10$8.65
    EMA 20$8.16
    EMA 50$7.34
    EMA 200$6.72

    MACD

    Line: 0.62Signal: 0.57Hist: 0.05

    ADX

    ADX: 42.6+DI: 33.3-DI: 10.4

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down16.0
    PSAR$8.60

    Bollinger Bands

    Upper Band$9.77
    Lower Band$6.45
    %B Position4094%(Upper)
    Band Width0.80

    RSI (14-Day)

    Overbought
    71.3

    Momentum Oscillators

    Stoch %K89.4
    Stoch %D87.5
    Williams %R-4.2
    ROC (10d)17.0%
    Momentum1.32
    CCI (20d)102.5
    MFI (14d)49.3

    Volatility Measures

    ATR (14d)$0.41(4.5%)
    StdDev (20d)0.83
    Hist Vol85.2%(High)

    Volume Flow

    VWAP$9.00
    OBV-21.8M
    AD Line-15.0M
    CMF (20d)0.329

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.8x
    VWMA (20d)$8.12

    Pivot Points

    R3$9.36
    R2$9.15
    R1$9.02
    Pivot Point$8.80
    S1$8.67
    S2$8.46
    S3$8.32

    Advanced Oscillators

    TSI38.47
    Ultimate Osc64.6
    KST347.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$84.08M$73.14M$90.30M$68.97M$69.39M$68.52M$78.95M$61.09M$66.91M$59.33M$61.00M$50.02M
    Cost of Revenue$26.90M$24.24M$31.01M$23.13M$24.07M$21.87M$26.31M$18.99M$19.84M$18.83M$22.23M$15.43M
    Gross Profit$57.18M$48.90M$59.29M$45.84M$45.32M$46.66M$52.63M$42.10M$47.07M$40.50M$38.77M$34.59M
    Operating Expenses$61.72M$55.74M$55.07M$57.34M$55.53M$61.83M$54.95M$57.57M$54.77M$49.42M$47.41M$48.03M
    R&D$1.89M$2.24M$3.48M$2.05M$1.84M$2.21M$2.43M$2.31M$2.35M$2.08M$6.81M$1.59M
    SG&A$57.05M$51.98M$54.66M$52.82M$56.67M$56.64M$50.24M$52.51M$50.15M$45.12M$43.06M$43.33M
    Operating Income$-4,543,000$-6,848,000$4.22M$-11,500,000$-10,210,000$-15,172,000$-2,314,000$-15,473,000$-7,702,000$-8,922,000$-8,635,000$-13,440,000
    Interest Income$296,000$285,000$263,000$479,000$479,000$710,000$789,000$928,000$1.03M$517,000$291,000$306,000
    Interest Expense$4.17M$3.98M$3.98M$4.09M$7.21M$4.42M$4.57M$4.76M$4.70M$4.70M$4.08M$3.79M
    Income Before Tax$-8,206,000$-10,418,000$515,000$-15,570,000$-17,089,000$-18,820,000$-6,351,000$-19,036,000$-11,307,000$-13,062,000$-11,725,000$-16,899,000
    Income Tax Expense$-154,000$256,000$385,000$167,000$53,000$72,000$440,000$134,000$43,000$47,000$106,000$24,000
    Net Income$-8,052,000$-10,674,000$130,000$-15,737,000$-17,142,000$-18,892,000$-6,791,000$-19,170,000$-11,350,000$-13,109,000$-11,831,000$-16,923,000
    EBITDA$-1,236,000$-3,678,000$7.16M$-9,338,000$-8,005,000$-12,988,000$-657,000$-13,639,000$-5,778,000$-7,043,000$-6,151,000$-11,676,000
    EBIT$-4,330,000$-6,728,000$4.23M$-11,955,000$-10,361,000$-15,115,000$-2,567,000$-15,200,000$-7,640,000$-8,877,000$-7,941,000$-13,419,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EOLS

    News

    Evolus Stock Price Forecast. Should You Buy EOLS?

    StockInvest.us has rated Evolus Inc. (EOLS) as a Buy Candidate with a technical score of 4.63, unchanged from its previous evaluation. The stock has shown positive short and long-term moving averages, indicating a positive forecast, and has risen 11.95% since a buy signal on August 12, 2026. Despite some negative signals like falling volume on rising prices and a MACD sell signal, the stock is seen as a buying opportunity due to its strong short-term trend and attractive risk-reward profile.

    StockInvest.us•8/29/26•
    Bullish

    August 2026's Leading Growth Companies With Insider Confidence

    The article highlights top growth companies in the United States with high insider ownership, indicating strong internal confidence. It details companies like Webull, Evolus, and Victoria's Secret, providing an overview of their operations, growth forecasts, and recent developments. The piece suggests that high insider ownership, coupled with robust earnings growth, makes these companies attractive investment prospects.

    Sahm•8/14/26•
    Bullish

    Renaissance Technologies LLC Lowers Stake in Evolus, Inc. $EOLS

    Renaissance Technologies LLC significantly reduced its stake in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the first quarter, selling 460,875 shares and retaining 339,025 shares valued at $1.39 million. Despite this, institutional investors collectively own about 90.69% of Evolus, and several other funds have recently increased or initiated positions. Analysts maintain a "Moderate Buy" consensus rating for Evolus with an average price target of $14.50, significantly higher than its recent share price of $8.12.

    MarketBeat•8/13/26•
    Somewhat-Bullish

    Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

    Assenagon Asset Management S.A. significantly increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 51.8% in the second quarter, now holding 908,180 shares valued at approximately $6.3 million. This move is part of a trend among institutional investors, who collectively own 90.69% of Evolus stock. The company maintains a "Moderate Buy" consensus rating from analysts, with shares trading above their 50-day and 200-day moving averages.

    MarketBeat•8/12/26•
    Bullish

    Trading Systems Reacting to (EOLS) Volatility

    This article analyzes Evolus Inc. (NASDAQ: EOLS) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment but a weak long-term outlook, identifying compelling upside potential as no resistance levels remain above the current price. The analysis provides specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis.

    Stock Traders Daily•8/10/26•
    Bullish

    Frequently Asked Questions About EOLS

    Does EOLS pay dividends?
    Evolus Inc (EOLS) does not currently pay a regular dividend.
    What is EOLS's market cap?
    Evolus Inc (EOLS) has a market capitalization of $600.40M with a current stock price of $9.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In